Introduction
Imatinib mesylate, an inhibitor of the oncogenic protein tyrosine kinase, Bcr-Abl, was developed as part of a program of rational drug design. 1, 2 Although clinical studies have established the undoubted efficacy of imatinib in treating patients in chronic phase chronic myeloid leukaemia (CML), [3] [4] [5] it appears to be far less beneficial in advanced phase disease. 6 In the latter, responses tend to be particularly short-lived and patients frequently develop resistance to the drug. The most common mechanism of resistance to imatinib is the selection of subclones which harbor point mutations in the Abl kinase domain that enable them to evade the cytotoxic effects of the inhibitor. 7 Antileukaemic agents which do not share imatinib's mode of action should be less vulnerable to the mechanisms that confer imatinib resistance on CML cells. Two such compounds are adaphostin 8 (NSC 680410), a tyrphostin and 17-demethoxygeldanamycin (17-AAG), 9 a benzoquinone ansamycin. Adaphostin is currently undergoing preclinical evaluation, 10, 11 although studies of 17-AAG have progressed to the clinical stage. 12 The molecular target of 17-AAG is the heat-shock protein 90 (Hsp90), a molecular chaperone protein that interacts with other client proteins to ensure that they remain in a functional and active state. 9 By binding to the adenosine triphosphate binding site within the N-terminus of Hsp90, 17-AAG disrupts this interaction causing the client protein to dissociate from Hsp90, which leads to its polyubiquitinylation and subsequent degradation via the 26S proteasome. 9 There is much interest in 17-AAG as a potential antileukaemic agent, as Bcr-Abl is a client of Hsp90. 13 In vitro treatment of CML cell lines with 17-AAG downregulates p210
Bcr-Abl protein levels and induces apoptotic cell death. 13, 14 Furthermore, 17-AAG may be effective in patients who have developed resistance to imatinib, as this compound has been shown to inhibit the growth of murine cell lines transformed with Bcr-Abl containing the E255K and T315I mutations. 15 In addition, the combination of 17-AAG with imatinib reportedly causes synergistic growth inhibition and induction of apoptosis in imatinib-resistant cell lines. 12 Synergistic induction of apoptosis in CML cells has also been reported for the combination of 17-AAG with the histone deactylase inhibitors, LBH589 16 and suberanoylanilide hydroxamic acid . 17 Adaphostin, the adamantyl ester of the tyrphostin AG957, was synthesized as a potential tyrosine kinase inhibitor. 8 Although AG957 interferes with the binding of substrates to Bcr-Abl and is a potent inhibitor of its tyrosine kinase activity, adaphostin is less potent in this regard. 8 Indeed, there is evidence to suggest that the cytotoxic effects of adaphostin on CML cells are not mediated via inhibition of Bcr-Abl. 18, 19 In contrast to imatinib, which rapidly abolishes tyrosine kinase activity and induces apoptosis gradually in the CML cell line K562, adaphostin induces rapid apoptosis and inhibits tyrosine phosphorylation more slowly. 18 Moreover, adaphostin has been reported to induce cell death in cell lines that do not express Bcr-Abl, including T-cell lymphoblastic leukaemia cells (Jurkat and CEM) 18, 20, 21 and murine myeloid cell lines such as FDC-P1 18 and Ba/F3. 10 Paradoxically, adaphostin does not exhibit selectivity for murine cell lines transformed with Bcr-Abl but does cause selective growth inhibition of CML granulocyte colony-forming units relative to normal progenitors. 18 Although the mechanisms underlying the apparent selectivity of adaphostin for primary CML cells remain elusive, it is still considered to have potential as an antileukaemic agent.
We have developed previously a unique series of murine cell line clones which express different amounts of Bcr-Abl and which model the different disease phases of CML. 22 In subsequent work, 23 we subjected one imatinib-sensitive clone, x6, to two independent rounds of imatinib exposure and obtained two imatinib-resistant subclones, x6-R and x6-R E255K . Whereas the latter clone has a mutation, E255K, within the kinase domain of Bcr-Abl, the former has no kinase domain mutations but overexpresses Bcr-Abl. These clones afforded us the opportunity for studying the effects of adaphostin and 17-AAG on cells with two mechanisms of imatinib resistance but having a common genetic background. In this study, we show that 17-AAG is selectively cytotoxic for Bcr-Abl-expressing cells and causes specific downregulation of Hsp90-associated proteins (Bcr-Abl and Akt). In contrast, adaphostin killed the murine cell lines indiscriminately, regardless of whether cells expressed Bcr-Abl or not. Furthermore, adaphostin treatment led to reduced protein levels for multiple cell signalling peptides (Bcr, Abl, Bcr-Abl, Akt and STAT5a (signal transducer and activator of transcription 5a)).
Materials and methods

Cell culture and cell lines
'RF10' culture medium consisted of RPMI 1640 supplemented with penicillin, streptomycin, L-glutamine and 10% fetal bovine serum. The 32D cell line was a gift from Dr Brian Druker (Oregon Health & Science University, Portland, OR, USA). This was maintained in RF10 further supplemented with 10% conditioned medium (c/m) from the WEHI-3B cell line, as a source of murine IL-3, herein referred to as 'complete medium'. Generation of the imatinib-sensitive and resistant 32D/BCR-ABL/GFP clones, x6, x6-R and x6-R E255K have been described elsewhere. 22, 23 Imatinib-sensitive clone x6 was maintained in complete medium and imatinib-resistant clones x6-R and x6-R E255K were grown in RF10 supplemented with 1 mM imatinib (Novartis Pharma, Basel, Switzerland).
Drug sensitivity assays
Cells were washed three times and resuspended in RF10. Serial dilutions of either adaphostin or 17-AAG (both from the National Cancer Institute, Bethesda, MD, USA) were added to cell suspensions seeded at 2 Â 10 5 cells/well in 24-well plates. Appropriate vehicle (dimethyl sulphoxide, DMSO) controls were included for each experiment. After 24 h, cells were washed, resuspended in 100 ml of RF10, stained with 10 mg/ml propidium iodide (PI) for 15 min, washed and resuspended in 100 ml of fresh RF10. Viable (non-PI-stained) cells were quantified on a FACSCalibur flow cytometer using 'CellQuest Pro' software (BD Biosciences, San Jose, CA, USA). Data were analysed by non-linear regression (Prism 4.0a, GraphPad Software, San Diego, CA, USA).
Measurement of intracellular reactive oxygen species
Reactive oxygen species (ROS) were detected using the cellpermeable dye 5-chloromethyl-2 0 ,7 0 -dichlorofluorescein diacetate (CM-H 2 DCFDA); Molecular Probes, Eugene, OR, USA). This dye is trapped within cells by de-esterification, where it reacts with peroxides to form the fluorescent product, 5-chloromethyl-2 0 -7 0 -dichlorofluorescein (DCF). Cells were washed three times, resuspended in RF10 and then incubated with 1 mM hydrogen peroxide (H 2 O 2 ; Sigma, Poole, Dorset, UK) 10 mM adaphostin or the appropriate vehicle control for 90 min. In addition, cells treated with H 2 O 2 were either pretreated, or not, for 30 min with the antioxidant 40 mM N-acetylcysteine (NAC; Sigma). Cells were then washed, resuspended in phosphate-buffered saline (PBS) containing either 10 mM CM-H 2 DCFDA or 0.01% (v/v) DMSO (vehicle control) and were stained by incubation at 371C for 30 min, in the dark. Excess, unreacted dye was removed by washing cells before resuspending them in 1 ml of ice-cold PBS. Fluorescence of stained and unstained cells was determined on channel FL-1 of a FACSCalibur flow cytometer.
Immunoblotting
Protein lysates were prepared from cells after 8-h culture, according to the method of Kabarowski et al. 24 Approximately 20 mg protein were electrophoresed on 8% SDS-polyacrylamide gel electrophoresis gels, blotted onto polyvinylidene difluoride membranes (Immobilon-P, Millipore, Billerica, MA, USA) and immunoscreened with anti-Abl (Ab-3, Calbiochem, San Diego, CA, USA) and anti-actin (Sigma-Aldrich) antibodies. Membranes were stripped in accordance with the manufacturer's instructions and reprobed, as necessary, with anti-Bcr (N-20), anti-STAT5 (C-17) (both from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-Akt (Cell Signaling Technology, Beverly, MA, USA) antibodies. Secondary antibodies were HRP-conjugated rabbit anti-mouse and swine anti-rabbit IgG (DAKO Corporation, Carpinteria, CA, USA). Immunoreactive bands were visualized by ECL (Amersham, Little Chalfont, Bucks, UK).
Results
We exposed each of the cell lines to doses of 17-AAG and adaphostin in the range of 0.1-30 mM for 24 h and assayed viability by PI staining and flow cytometry (Figure 1 ). BcrAbl-expressing cell lines (x6, x6-R and x6-R E255K) were selectively killed by 17-AAG as evidenced by mean IC 50 values which were substantially lower than those for the BcrAbl-negative, parental cell line, 32D (Table 1 ). In contrast, adaphostin exhibited no such selectivity, as the mean IC 50 value for 32D was not significantly different from those obtained for any of the Bcr-Abl-expressing lines (Table 1) . One of the imatinib-resistant clones, x6-R, which overexpresses Bcr-Abl (Figure 2a ) was found to exhibit moderate cross-resistance to 17-AAG, having a mean IC 50 of 1.70 mM relative to the parental imatinib-sensitive clone, x6, which had a mean IC 50 of 0.90 mM (Table 1) . Conversely, this same imatinib-resistant clone was the most sensitive to adaphostin among all the cell lines tested ( Table 1) . Neither of the imatinib-resistant cell lines exhibited cross-resistance to adaphostin.
Adaphostin induced a dose-dependent downregulation of Abl and/or p210 Bcr-Abl Bcr, STAT5a and Akt in both Bcr-Abl-negative (32D) and Bcr-Abl-positive (x6, x6-R, x6-R E255K ) cell lines (Figure 2b ). Downregulation of Abl by 5 mM adaphostin was accompanied by a lower molecular weight species, presumably a degradation product, which was immunoreactive for the antiAbl antibody (Figure 2b ). In contrast, 17-AAG selectively inhibited the expression of p210
Bcr-Abl and Akt proteins (Figure 2b) . Maximum downregulation was achieved at the lowest dose of 17-AAG (1 mM) and higher doses produced no further effect (Figure 2b) .
As adaphostin has been suggested to induce cell death by inducing the production of intracellular ROS, we assessed whether this was the case in each of the cell lines. Incubation of cells with 10 mM adaphostin for 90 min failed to induce substantial ROS, because the DCF fluorescence was comparable to that of the vehicle controls (Figure 3) . In contrast, a 90 min incubation in 1 mM H 2 O 2 produced substantial increases in DCF fluorescence in all of the cell lines, which could be partially (32D, x6, x6-R) or wholly (x6-R E255K ) reversed by pretreating the cells with 40 mM NAC for 30 min (Figure 3) . Treatment of cells with lower doses of adaphostin (0.1, 1 mM) did not result in increased DCF fluorescence indicative of greater ROS production and a higher dose of adaphostin (100 mM) caused rapid cell death (data not shown). To investigate whether prolonged treatment with 1 mM H 2 O 2 would result in cell death comparable to that achieved with 10 mM adaphostin, we incubated each of the cell lines with both compounds for 24 h (Table 2) . Whereas, adaphostin-treatment caused almost complete cell death (o5% viable cells remaining) in all of the cell lines, H 2 O 2 treatment was less toxic to Bcr-Abl-expressing cells (440% viable cells remaining; Table 2 ).
Discussion
In this work we show that adaphostin is capable of inducing the rapid downregulation of multiple cell signalling proteins, in addition to its previously reported inhibitory effects upon expression of p210
Bcr-Abl10,18,19,25 Raf-1 21 and cyclin D1. 21 The affected peptides were a tyrosine kinase (wild-type Abl), serine-threonine kinases (Akt and wild-type Bcr) and a transcription factor (STAT5a). Downregulation of these species was not confined to Bcr-Abl-expressing cells as dose-dependent inhibition of expression of all four proteins was also detected in parental 32D cells treated with adaphostin. Yu et al. 21 have reported that exposing Bcr-Abl-negative Jurkat cells to a 2 mM dose of adaphostin for 6 h resulted in a modest reduction in levels of Akt. Our findings extend this observation, because we obtained a clear and substantial decline in Akt protein in all cell lines tested, at higher doses of adaphostin (5 and 10 mM), and can thus positively identify this kinase as being a target for adaphostin-mediated downregulation.
In keeping with the reported ability of 17-AAG to induce apoptosis selectively in Bcr-Abl-expressing cell lines, 13 we obtained potent cell killing for each of the Bcr-Abl-transformed clones (x6, x6-R and x6-R E255K ). In contrast, the absence of BcrAbl does not confer insensitivity to adaphostin on 32D cells, as their mean IC 50 for this drug was not significantly different (P40.05; Mann-Whitney test) from that of 32D/BCR-ABL/GFP clone x6(1.03 and 1.92 mM, respectively). Our findings are in agreement with those of others, 10, 18 who found a similar lack of selectivity for cell death induced by adaphostin in murine cell lines.
The mechanism by which adaphostin downregulates proteins is unclear, and previous attempts to illuminate this process through the use of inhibitors have yielded disparate results. 19, 21, 26 Hence, the ability of adaphostin to reduce the expression of Bcr-Abl has been reported as being unchanged by treatment with proteasome inhibitors (bortezomib (PS-341)), inhibitors of translation (cycloheximide) and antioxidants (NAC). 19 In contrast, it has been shown that adaphostin-induced downregulation of Raf-1 and cyclin D1, in Jurkat cells, can be inhibited by NAC. 21 Moreover, rather than antagonizing protein degradation, the combination of the proteasome inhibitor, bortezomib, with adaphostin was found to enhance downregulation of Raf-1. 26 Inhibition of protein synthesis by adaphostin has been demonstrated in human T-lymphoblastic leukaemia cell lines, 20 but this would not account for the sudden loss of stability of pre-existing proteins that we observed for adaphostin-treated cells. It has also been reported that the prototypical tyrphostin, AG957, effectively depletes p210
Bcr-Abl by covalently crosslinking it into higher molecular weight complexes, 27 but it is unclear whether adaphostin shares this property.
The issue of whether imatinib-resistant cells exhibit crossresistance to adaphostin is also controversial. Similarly to our findings, no such effect has been detected in some studies, 10, 18 Cell lines were exposed to either 1 mM H 2 O 2 or 10 mM adaphostin for 24 h. Cell viability was determined by propidium iodide staining followed by flow cytometry. Data are the mean7s.e.m. from three independent experiments.
Adaphostin downregulates multiple proteins DJ Barnes et al whereas cross-resistance to adaphostin has recently been reported for the imatinib-resistant human cell lines, KBM5-R and KBM7-R. 28 However, the clinical significance of the latter findings is unclear, as the same authors report that primary cells from CML patients who developed resistance to imatinib do not exhibit similar cross-resistance. 28 Intriguingly, the most sensitive cell line to adaphostin was clone x6-R, which had acquired imatinib-resistance via overexpression of Bcr-Abl. 22 It has been proposed that adaphostin induces cytotoxicity by stimulating intracellular ROS generation and that this action of the drug is distinct from its inhibitory effects upon protein expression. 10 Moreover, it has been suggested that cells that overexpress Bcr-Abl may be especially susceptible to adaphostin-induced oxidative stress 10 as Bcr-Abl expression, per se, has been reported to induce ROS production in haemopoietic cells. 29 However, we failed to observe enhanced ROS production by any of our cell lines when incubated with adaphostin. Under identical conditions, intracellular peroxide, generated by incubating cells with 1 mM H 2 O 2 , was readily detectable as an increase in DCF fluorescence suggesting that our assay was adequate for detecting ROS. Furthermore, whereas 24-h exposure to 10 mM adaphostin resulted in almost complete killing of clone x6-R (mean viability ¼ 3.43%), incubation with 1 mM H 2 O 2 for the same period was far less cytotoxic (mean viability ¼ 76.4%; Table 2 ). Although we cannot rule out the possibility that the cytotoxic effects of adaphostin are due, either wholly or in part, to stimulated ROS production, our findings would tend to argue against this being the case for these 32D-derived cell lines. In addition, enforced ectopic expression of MEK in Jurkat has been shown to abrogate the cytotoxic effects of adaphostin without affecting its ability to stimulate ROS. 21 These authors have interpreted this finding, together with the results of a subsequent study, 26 as implicating downregulation of the cytoprotective Raf/MEK/ERK pathway coupled with a concomitant stimulation of the pro-apototic, 'stress-related' JNK pathway as being a possible mechanism responsible for adaphostin-induced cell death. It is possible that adaphostin could induce apoptosis via dysregulation of these pathways without a 'need' for excessive ROS production. A final point concerning the adaphostin sensitivity of our cell lines is that the imatinib-sensitive clone, x6, was less sensitive to the cytotoxic actions of adaphostin than the imatinib-resistant clones, x6-R and x6-R E255K . A similar observation has been made for Ph þ cells from patients who had never been treated with imatinib and which are apparently less sensitive to in vitro treatment with adaphostin than cells from patients who had developed resistance to imatinib. 10 Of the proteins evaluated by immunoblotting, Abl, Bcr, STAT5a and actin were unaffected by 17-AAG treatment, indicating that their stability did not depend upon an association with Hsp90. Downregulation of p210
Bcr-Abl and Akt was observed, as both are well-known partners of Hsp90. 13, 30 In contrast to its behavior when treated with adaphostin, where it proved to be the most sensitive cell line, the imatinib-resistant clone x6-R was the least sensitive to 17-AAG of the BcrAbl-positive clones. This is most likely owing to the high degree of p210
Bcr-Abl overexpression in this clone, which permits it to grow in 1 mM imatinib. 22 It follows that higher doses of 17-AAG are required to inhibit Hsp90 in the presence of increased amounts of Bcr-Abl protein. Similar findings have been reported for the imatinib-resistant CML cell lines K562-R and LAMA84-R when treated with 17-AAG. 12, 31 It could be argued, from a therapeutic perspective, that inhibiting Bcr-Abl in Ph þ cells is always desirable and that concurrent downregulation of STAT5a and Akt might prove to be clinically advantageous because both proteins contribute to leukaemogenesis in CML. 32, 33 However, the consequences of downregulating Bcr, Abl, STAT5a and Akt, in addition to Bcr-Abl, may not be unequivocally positive. We have shown that adaphostin lacks selectivity and inhibits expression of these proteins in cells lacking Bcr-Abl, so it is probable that this drug will affect non-leukaemic tissues as well as CML cells. Bcr has recently been shown to act as a tumour suppressor in the Wnt pathway 34 and downregulation of Akt may be especially problematic, as inhibitors of Akt-signalling have been responsible for occurrences of impaired glucose tolerance, hyperglycemia and type II diabetes (reviewed in Martelli et al.
35
). If these side effects prove to be significant, 17-AAG might actually be as potentially harmful as adaphostin, because it also causes downregulation of Akt.
In conclusion, we showed that both 17-AAG and adaphostin share the property of being able to induce rapid downregulation of p210
Bcr-Abl and Akt protein levels. The similarity ends here, however, as the cytotoxicity of 17-AAG is a direct consequence of its ability to downregulate Bcr-Abl protein levels, it is unclear whether this is required for adaphostin-mediated cell killing. We suggest that it is doubtful that oxidative stress alone, caused by a putative stimulation of ROS production, can account for the potent negative effect of adaphostin upon viability, which we observe in our cell lines. In addition, we have shown that although adaphostin inhibits multiple targets through an, as yet unknown, mechanism, 17-AAG exerts its effects via a welldefined action on the subset of cellular proteins requiring Hsp90 as a molecular chaperone. Further studies, in vitro, in vivo and in the clinic will be needed to determine which mode of action produces the greatest therapeutic benefit with the fewest side effects.
